Home
»
Press Room
»
Vaccine Packaging Market Size To Reach $2.88Bn By 2030

Vaccine Packaging Market Size To Reach $2.88 Billion By 2030

May 2025 | Report Format: Electronic (PDF)

Vaccine Packaging Market Growth & Trends

The global vaccine packaging market size is anticipated to reach USD 2.88 billion by 2030 and is projected to grow at a CAGR of 7.5% during the forecast period, according to a new report by Grand View Research, Inc. The increasing dominance of biologics, including mRNA vaccines, recombinant vaccines, and viral vector-based formulations, has significantly influenced packaging needs. These vaccines are often highly temperature-sensitive, requiring specialized packaging solutions that can maintain a strict cold chain throughout the supply and distribution process.

For instance, mRNA vaccines like Pfizer-BioNTech and Moderna require ultra-cold storage, which demands insulated and trackable packaging systems that preserve efficacy and integrity. This shift has created a surge in demand for high-performance materials such as borosilicate glass, high-barrier plastics, and specialized closures with high chemical resistance and sealing capability. The need to maintain stringent thermal protection and sterility is directly fueling innovation and growth in vaccine packaging formats.

As vaccine distribution expands globally, regulatory scrutiny around safety, authenticity, and traceability of packaging materials has intensified. Agencies such as the U.S. FDA, European Medicines Agency (EMA), and India’s CDSCO enforce strict regulations concerning packaging integrity, material safety, and serialization for traceability. These guidelines are designed to minimize contamination, dosing errors, and counterfeit products in the market. To comply, pharmaceutical companies are investing in tamper-proof packaging, child-resistant closures, and smart labeling systems embedded with barcodes or RFID technology. These regulatory pressures are driving both the volume and technological sophistication of vaccine packaging products.

Pharmaceutical manufacturing is expanding rapidly in regions such as Asia Pacific, Latin America, and parts of the Middle East and Africa. Countries such as India, China, Brazil, and Indonesia are not only manufacturing vaccines for domestic use but also for export. This has led to a rise in demand for cost-effective, high-volume packaging solutions that comply with global quality and regulatory standards. These regions are increasingly becoming major hubs for contract manufacturing organizations (CMOs) and pharmaceutical exporters, which in turn drives growth in both bulk and unit-dose vaccine packaging. The growth in local production also means that packaging must now address challenges such as long-distance transport, fluctuating temperatures, and regulatory diversity, further expanding the role and complexity of packaging solutions.

Compliance with FDA, EMA, and WHO prequalification standards also plays a significant role in determining market competitiveness. Companies that can navigate multinational regulatory frameworks and offer packaging that ensures sterility, compatibility, and traceability are better positioned to secure contracts from global vaccine manufacturers and public health bodies like GAVI and UNICEF. This has intensified the need for third-party audits, real-time quality assurance systems, and standardized production across geographies, pushing many companies to invest in global harmonization of quality systems and modular packaging lines.

The vaccine packaging industry is highly dynamic, where long-term growth depends not only on technological superiority and cost competitiveness, but also on the ability to scale responsibly, comply globally, and adapt to new vaccine delivery paradigms. As global health challenges continue to evolve, the competitive intensity is expected to increase, with strategic alliances, product innovation, and operational excellence being the keys to sustained market leadership.

key Request a free sample copy or view report summary: Vaccine Packaging Market Report

Vaccine Packaging Market Report Highlights

The glass material segment held the largest share of over 60.7% of the market in 2024. Glass offers excellent barrier protection against oxygen and moisture, which is crucial for vaccines that are highly sensitive to environmental exposure. Unlike most plastic materials, glass does not allow any permeability, ensuring extended shelf life and sterility.
The vials product segment is expected to grow at the fastest CAGR of 30.4% during the forecast period. This is on account of their cost-effectiveness, scalability, compatibility with cold chains, and strong regulatory track record. Their global availability and infrastructure alignment with high-throughput production make them indispensable in both commercial and public health settings.
Based on application, the vaccine manufacturers segment held the largest revenue share of over 49.9% in 2024. Vaccine manufacturers dominate the global market for vaccine packaging due to their foundational role in the production process, direct involvement in fill-finish and compliance, and their strategic partnerships with packaging suppliers.
The North American region dominated the market and accounted for the largest global revenue share of over 34.2% in 2024, and it is also projected to grow at the fastest CAGR of 7.1% during the forecast period.